What is the future of ocular lubricants in dry eye treatment?

8 May 2019
Spring 2019

Léa Surugue looks at the dynamic expansion of next-generation artificial tears, and asks what other tailored products are emerging.

The TFOS DEWS II report of 2017 established the idea that dry eye disease (DED) is a multifactorial disorder. Manifesting itself with varying degrees of severity, DED requires a variety of treatment approaches. Research has been moving along quickly to discover new products that can best address this complexity, while recognising the difficulty of finding a universal treatment for all. 

Until now, traditional ocular lubricants have tended to offer patients only a palliative approach to dry eye symptom management, without necessarily trying to resolve the causes of the disorder. 

Jennifer Craig FCOptom, Vice-Chair and one of the lead authors of the TFOS DEWS II report, explains: “New lubricants are working harder than ever to address the different reasons people have dry eyes, which often requires complex combinations of features within the drops. 

Sign in to continue

Forgotten password?
Register

Not already a member of The College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

We believe that vaccine uptake will be maximised where staff are supported to make their own decisions, having been provided with clear, evidence-based information on the benefit and value of vaccinations.

Following the announcement by the Secretary for Health that the isolation period for people who test positive for COVID-19 will be cut to five full days in England, NHSE has confirmed this will apply in primary care settings.

UKHSA confirms that changes to the self-isolation period following Covid exposure applies to healthcare workers